BigHat Biosciences

BigHat Biosciences is a biotechnology company focused on designing safer, more effective antibody therapies using machine learning and synthetic biology. The company leverages its Milliner platform, which integrates a high-speed wet lab with state-of-the-art machine learning technologies, to discover and engineer antibodies for intractable diseases like infections and cancers. Their approach promises to deliver next-generation therapies with improved safety and efficacy. Based outside San Francisco, BigHat Biosciences engages in strategic collaborations and partnerships to enhance their therapeutic programs and has raised significant funding to pursue these innovative solutions.